SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001472375-24-000005
Filing Date
2024-02-05
Accepted
2024-02-05 15:07:59
Documents
46
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT FOR THE PERIOD ENDED DECEMBER 31, 2023 ixform10q.htm   iXBRL 10-Q 428793
2 CERTIFICATION exhibit31-1.htm EX-31.1 11635
3 CERTIFICATION exhibit31-2.htm EX-31.2 11899
4 CERTIFICATION exhibit32-1.htm EX-32.1 4324
5 CERTIFICATION exhibit32-2.htm EX-32.2 4333
6 regenerexlogo.gif GRAPHIC 5716
  Complete submission text file 0001472375-24-000005.txt   2367299

Data Files

Seq Description Document Type Size
7 SCHEMA DOCUMENT rgpx-20231231.xsd EX-101.SCH 20248
8 CALCULATION LINKBASE DOCUMENT rgpx-20231231_cal.xml EX-101.CAL 31423
9 DEFINITION LINKBASE DOCUMENT rgpx-20231231_def.xml EX-101.DEF 95433
10 LABELS LINKBASE DOCUMENT rgpx-20231231_lab.xml EX-101.LAB 171520
11 PRESENTATION LINKBASE DOCUMENT rgpx-20231231_pre.xml EX-101.PRE 148863
47 EXTRACTED XBRL INSTANCE DOCUMENT ixform10q_htm.xml XML 173092
Mailing Address 5348 VEGAS DRIVE, SUITE 177 LAS VEGAS NV 89108
Business Address 5348 VEGAS DRIVE, SUITE 177 LAS VEGAS NV 89108 305-927-5191
REGENEREX PHARMA, INC. (Filer) CIK: 0001357878 (see all company filings)

IRS No.: 980479983 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 000-53230 | Film No.: 24595391
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)